




Targeted DEP™ outperforms leading treatments in ovarian cancer model

Melbourne, Australia; 16 November 2015: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that treatment with its novel antibody-targeted DEP® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model.

Starpharma's antibody-targeted DEP™ conjugate (using Herceptin as the targeting group) significantly outperformed both Roche's Kadcyła® (T-DM1), a Herceptin® antibody-drug conjugate (ADC), and the monoclonal antibody Herceptin® (Trastuzumab) itself in the pre-clinical ovarian cancer model. Efficacy performance is illustrated in the graph below.


Efficacy of Targeted DEP™ Herceptin Conjugate vs Kadcyła®

in Ovarian* Cancer Model




*SKOV-3 Ovarian cancer xenograft in NOD-SCID mice (5-6/group)
 Saline, Kadcyła (10mg/kg) and Targeted DEP™ conjugate were dosed once/wk for 3 wks; Herceptin (20mg/kg) dosed twice/wk for 3 wks. p=0.0011

The targeted DEP™ treated group showed vastly improved anticancer effectiveness and survival compared to both Kadcyła® and Herceptin®. The targeted DEP™ treated group exhibited complete regression after treatment which has been maintained for the duration of the experiment (60 days, experiment ongoing). In contrast, in the Kadcyła® group, only tumour stasis was observed during treatment with a maximum inhibition of 32% at day 12, however soon after completion of dosing tumour regrowth occurred.



Survival statistics for the targeted DEP™ conjugate were also impressive with 100% of the targeted DEP™ treated group surviving at 60 days (study still ongoing), whereas by day 50, none of the Kadcyła® treated group were alive. Survival results are presented below.

Survival : Targeted DEP™ Herceptin Conjugate vs Kadcyła®
in Ovarian Cancer Model




“We are very excited by these latest results for our targeted DEP™ conjugates and feedback from commercial parties on this new data has been very positive indeed. Discussions are now underway with a number of pharmaceutical companies in relation to this targeted DEP™ conjugate and the application of Starpharma’s targeted DEP™ platform to their proprietary drugs.”

The top 3 antibody based treatments in cancer (Rituxan, Avastin and Herceptin) had total sales in excess of \$US20B in 2014. Targeted therapies for cancer such as the ADCs Kadcyra[®] and Adcetris[®] had combined sales in excess of US\$1billion in 2014, with Kadcyra[®] sales growing at 144% versus the previous year. The market for ADCs is expected to grow to US\$9 billion annually by 2023.¹

Targeted DEP[™] Conjugates

Starpharma's proprietary targeted DEP[™] conjugate in this experiment consist of a dendrimer scaffold, a targeting group (in this case the monoclonal antibody trastuzumab (Herceptin[®])) and a "payload" of anticancer drug.

Targeted DEP[™] conjugates have a number of important advantages over standard ADCs including higher drug loading and manufacturing advantages.



ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development programs: VivaGel[®] portfolio, DEP[™] drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead products are based on VivaGel[®] (SPL7013, astodimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel[®] formulated as a water based gel and delivered vaginally now has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries. Inc., (TSE: JP3192800005) to market a value-added, VivaGel[®] condom. The VivaGel[®] condom is available for purchase in Australia under Ansell's Lifestyles[®] Dual Protect[™] brand. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles[®], ZERO[®] and SKYN[®]. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market.

In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced, or DEP[™] versions of existing drugs are under development. The most advanced of these is DEP[™] docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere[®]), which is in clinical development in patients with solid tumours. In preclinical studies DEP[™] docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere[®] (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP[™] drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets.

¹ Roots Analysis, Antibody Drug Conjugates Market, 2014-2024

In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®). For more information please visit: www.starpharma.com

FOR FURTHER INFORMATION

Media:

Buchan Consulting

Rebecca Wilson

Mob: +61 417 382 391

rwilson@buchanwe.com.au

Gabriella Hold

+61 3 9866 4722

ghold@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer

Nigel Baade, CFO and Company Secretary

+61 3 8532 2704

investor.relations@starpharma.com

www.starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.